Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions.

IF 5.7 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Current Atherosclerosis Reports Pub Date : 2024-04-01 Epub Date: 2024-03-05 DOI:10.1007/s11883-024-01193-8

Melody Hermel, Andrew Chiou, Abdul Mannan Khan Minhas, Maha Inam, Carly E Waldman, Eventine Youngblood, Sandeep Mehta, Leandro Slipczuk, Sana Sheikh, Chelsea Meloche, Adeel Khoja, Salim S Virani

{"title":"Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions.","authors":"Melody Hermel, Andrew Chiou, Abdul Mannan Khan Minhas, Maha Inam, Carly E Waldman, Eventine Youngblood, Sandeep Mehta, Leandro Slipczuk, Sana Sheikh, Chelsea Meloche, Adeel Khoja, Salim S Virani","doi":"10.1007/s11883-024-01193-8","DOIUrl":null,"url":null,"abstract":"Purpose of review: Focused review highlighting ten select studies presented at the 2023 American Heart Association (AHA) Scientific Sessions.Recent findings: Included studies assessed semaglutide and cardiovascular outcomes in overweight or obese patients without diabetes (SELECT); dapagliflozin in patients with acute myocardial infarction without diabetes (DAPA-MI); effects of dietary sodium on systolic blood pressure in middle-aged individuals (CARDIA-SSBP); long-term blood pressure control after hypertensive pregnancy with physician guided self-management (POP-HT); effect and safety of zilebesiran, an RNA interference therapy, for sustained blood pressure reduction (KARDIA-1); recaticimab add-on therapy in patients with non-familial hypercholesterolemia and mixed hyperlipidemia (REMAIN-2); efficacy and safety of lepodisiran an extended duration short-interfering RNA targeting lipoprotein(a); safety and pharmacodynamic effects of an investigational DNA base editing medicine that inactivates the PCSK9 gene and lowers LDL cholesterol (VERVE-101); automated referral to centralized pharmacy services for evidence-based statin initiation in high-risk patients; and effects of intensive blood pressure lowering in reducing risk of cardiovascular events (ESPRIT). Research presented at the 2023 AHA Scientific Sessions emphasized innovative strategies in cardiovascular disease prevention and management.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":" ","pages":"119-131"},"PeriodicalIF":5.7000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Atherosclerosis Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11883-024-01193-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Focused review highlighting ten select studies presented at the 2023 American Heart Association (AHA) Scientific Sessions.

Recent findings: Included studies assessed semaglutide and cardiovascular outcomes in overweight or obese patients without diabetes (SELECT); dapagliflozin in patients with acute myocardial infarction without diabetes (DAPA-MI); effects of dietary sodium on systolic blood pressure in middle-aged individuals (CARDIA-SSBP); long-term blood pressure control after hypertensive pregnancy with physician guided self-management (POP-HT); effect and safety of zilebesiran, an RNA interference therapy, for sustained blood pressure reduction (KARDIA-1); recaticimab add-on therapy in patients with non-familial hypercholesterolemia and mixed hyperlipidemia (REMAIN-2); efficacy and safety of lepodisiran an extended duration short-interfering RNA targeting lipoprotein(a); safety and pharmacodynamic effects of an investigational DNA base editing medicine that inactivates the PCSK9 gene and lowers LDL cholesterol (VERVE-101); automated referral to centralized pharmacy services for evidence-based statin initiation in high-risk patients; and effects of intensive blood pressure lowering in reducing risk of cardiovascular events (ESPRIT). Research presented at the 2023 AHA Scientific Sessions emphasized innovative strategies in cardiovascular disease prevention and management.

查看原文本刊更多论文

在 2023 年美国心脏协会科学会议上介绍的心血管疾病预防研究要点。

综述目的：重点回顾在2023年美国心脏协会（AHA）科学会议上发表的十项精选研究：纳入的研究评估了semaglutide和无糖尿病的超重或肥胖患者的心血管预后（SELECT）；达帕利氟嗪在无糖尿病的急性心肌梗死患者中的应用（DAPA-MI）；膳食钠对中年人收缩压的影响（CARDIA-SSBP）；妊娠高血压患者在医生指导下自我管理的长期血压控制（POP-HT）；RNA 干扰疗法 zilebesiran 用于持续降低血压的效果和安全性（KARDIA-1）；非家族性高胆固醇血症和混合型高脂血症患者的雷西替单抗附加疗法（REMAIN-2）；针对脂蛋白（a）的长效短干扰 RNA Lepodisiran 的有效性和安全性；一种可使 PCSK9 基因失活并降低低密度脂蛋白胆固醇的试验性 DNA 碱基编辑药物 (VERVE-101) 的安全性和药效学效应；自动转诊至集中药房服务，以便为高危患者启动循证他汀类药物治疗；以及强化降压在降低心血管事件风险方面的效果 (ESPRIT)。在 2023 年美国心脏病学会科学会议上发表的研究报告强调了心血管疾病预防和管理的创新策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Atherosclerosis Reports 医学-

CiteScore

9.00

自引率

3.40%

发文量

审稿时长

6-12 weeks

期刊介绍： The aim of this journal is to systematically provide expert views on current basic science and clinical advances in the field of atherosclerosis and highlight the most important developments likely to transform the field of cardiovascular prevention, diagnosis, and treatment. We accomplish this aim by appointing major authorities to serve as Section Editors who select leading experts from around the world to provide definitive reviews on key topics and papers published in the past year. We also provide supplementary reviews and commentaries from well-known figures in the field. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.